ERBB2 in pediatric cancer: Innocent until proven guilty

被引：24

作者：

Gilbertson, RJ

机构：

[1] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA

[2] St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA

来源：

ONCOLOGIST | 2005年 / 10卷 / 07期

关键词：

ERBB2; medulloblastoma; pediatric cancer; molecular drug target;

D O I：

10.1634/theoncologist.10-7-508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Adult oncologists and their research colleagues have "led the charge" in the war on cancer. Their efforts have generated effective new chemotherapies that target cancer causing molecular alterations. It is hoped that these successes will be repeated within the pediatric oncology community. Testing whether molecular targeted therapies of adult cancers are also effective against childhood cancers might allow the rapid introduction of these exciting new agents into the pediatric clinic. However, it is imperative that we do not introduce blindly these agents into the pediatric population. We must ensure that molecular targets in adult cancers also fulfill a number of important criteria within the pediatric disease. This review addresses the issues surrounding the identification of molecular targets in pediatric cancers by focusing on studies of the ERBB2 oncogene.

引用

收藏

页码：508 / 517

页数：10

相关论文

共 107 条

[1] Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase [J].

Adam, L ;

Vadlamudi, R ;

Kondapaka, SB ;

Chernoff, J ;

Mendelsohn, J ;

Kumar, R .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (43) :28238-28246

[2] ErbB2 expression is correlated with increased survival of patients with osteosarcoma [J].

Akatsuka, T ;

Wada, T ;

Kokai, Y ;

Kawaguchi, S ;

Isu, K ;

Yamashiro, K ;

Yamashita, T ;

Sawada, N ;

Yamawaki, S ;

Ishii, S .

CANCER, 2002, 94 (05) :1397-1404

[3] The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions [J].

Alroy, I ;

Yarden, Y .

FEBS LETTERS, 1997, 410 (01) :83-86

[4] Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis [J].

Andrechek, ER ;

Hardy, WR ;

Siegel, PM ;

Rudnicki, MA ;

Cardiff, RD ;

Muller, WJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3444-3449

[5] Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas [J].

Anninga, JK ;

van de Vijver, MJ ;

Cleton-Jansen, AM ;

Kristel, PMP ;

Taminiau, AHM ;

Nooij, M ;

Egeler, RM ;

Hogendoorn, PCW .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (07) :963-970

[6] INCREASED TYROSINE KINASE-ACTIVITY ASSOCIATED WITH THE PROTEIN ENCODED BY THE ACTIVATED NEU ONCOGENE [J].

BARGMANN, CI ;

WEINBERG, RA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (15) :5394-5398

[7] MULTIPLE INDEPENDENT ACTIVATIONS OF THE NEU ONCOGENE BY A POINT MUTATION ALTERING THE TRANSMEMBRANE DOMAIN OF P185 [J].

BARGMANN, CI ;

HUNG, MC ;

WEINBERG, RA .

CELL, 1986, 45 (05) :649-657

[8] ONCOGENIC ACTIVATION OF THE NEU-ENCODED RECEPTOR PROTEIN BY POINT MUTATION AND DELETION [J].

BARGMANN, CI ;

WEINBERG, RA .

EMBO JOURNAL, 1988, 7 (07) :2043-2052

[9]

BEGON D, 2005, J BIOL CHEM 0503

[10] An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors [J].

Burgess, AW ;

Cho, HS ;

Eigenbrot, C ;

Ferguson, KM ;

Garrett, TPJ ;

Leahy, DJ ;

Lemmon, MA ;

Sliwkowski, MX ;

Ward, CW ;

Yokoyama, S .

MOLECULAR CELL, 2003, 12 (03) :541-552

← 1 2 3 4 5 6 7 8 9 10 →